Tumor targeted engineered stem cells for treatment of lung cancer
Congressional District Code:
Biomedical Laboratory R&D
October 2017 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
This proposal aims to explore and test a novel targeted oncolytic viro-cell therapy using the mesenchymal stem cells (MSCs) infected by harmless common cold virus, the respiratory syncytial virus (RSV) for treatment of lung cancers, which is the number one killer among cancers worldwide. Despite advances in the treatment and improvement in outcomes, the 5-year survival rates remain very poor (15% or less) for non–small cell lung cancers (NSCLC), which constitute ~85% of all lung cancer patients....